Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy sit down with our community to share their progress and answer your questions.

Sarah Boyce, Avidity CEO, Dr. Steve Hughes, Avidity CMO, and Dr. Nicholas Johnson, MARINA Principal Investigator, present topline data from the MARINA Phase 1/2 clinical trial evaluating AOC 1001 for adults with myotonic dystrophy type 1 (DM1).

Learn more about Avidity Biosciences at https://www.aviditybiosciences.com/

Presenters include:
+ Sarah Boyce, President & CEO
+ Steve Hughes, MD, Chief Medical Officer
+ Nicholas E. Johnson, M.D., M.Sci., FAAN, Vice Chair for Research, Department of Neurology, Virginia Commonwealth University

Find all our recorded Meet the DM Drug Developer sessions at https://www.myotonic.org/meet-dm-drug...